184 related articles for article (PubMed ID: 18629841)
1. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting.
Gallagher DJ; Milowsky MI; Bajorin DF
Cancer; 2008 Sep; 113(6):1284-93. PubMed ID: 18629841
[TBL] [Abstract][Full Text] [Related]
2. Vinflunine in the treatment of advanced bladder cancer.
Mamtani R; Vaughn DJ
Expert Rev Anticancer Ther; 2011 Jan; 11(1):13-20. PubMed ID: 21166506
[TBL] [Abstract][Full Text] [Related]
3. The evolving role of chemotherapy in advanced urothelial cancer.
Calabrò F; Sternberg CN
Curr Opin Support Palliat Care; 2007 Oct; 1(3):180-6. PubMed ID: 18685360
[TBL] [Abstract][Full Text] [Related]
4. Second-line therapy in bladder cancer.
Bachner M; De Santis M
Curr Opin Urol; 2009 Sep; 19(5):533-9. PubMed ID: 19550334
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer.
Kollmannsberger C; Bokemeyer C
Curr Opin Support Palliat Care; 2008 Sep; 2(3):167-72. PubMed ID: 18685416
[TBL] [Abstract][Full Text] [Related]
6. Current treatment of metastatic bladder cancer and future directions.
Lei AQ; Cheng L; Pan CX
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1851-62. PubMed ID: 22117153
[TBL] [Abstract][Full Text] [Related]
7. Nonplatinum therapy in advanced bladder cancer.
Srinivas S; Colocci N
Expert Rev Anticancer Ther; 2006 Jun; 6(6):887-94. PubMed ID: 16761932
[TBL] [Abstract][Full Text] [Related]
8. Systemic chemotherapy for advanced bladder cancer: update and controversies.
Garcia JA; Dreicer R
J Clin Oncol; 2006 Dec; 24(35):5545-51. PubMed ID: 17158540
[TBL] [Abstract][Full Text] [Related]
9. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Oing C; Rink M; Oechsle K; Seidel C; von Amsberg G; Bokemeyer C
J Urol; 2016 Feb; 195(2):254-63. PubMed ID: 26410730
[TBL] [Abstract][Full Text] [Related]
10. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.
De Santis M; Bachner M
Curr Opin Urol; 2007 Sep; 17(5):363-8. PubMed ID: 17762632
[TBL] [Abstract][Full Text] [Related]
11. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.
Ortmann CA; Mazhar D
Future Oncol; 2013 Nov; 9(11):1637-51. PubMed ID: 24156324
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise.
Zachos I; Konstantinopoulos PA; Tzortzis V; Gravas S; Karatzas A; Karamouzis MV; Melekos M; Papavassiliou AG
Expert Opin Investig Drugs; 2010 Jul; 19(7):875-87. PubMed ID: 20528482
[TBL] [Abstract][Full Text] [Related]
13. [Treatment strategies for metastatic patients in bladder cancer].
Théodore C
Bull Cancer; 2010; 97 Suppl Cancer de la vessie():27-33. PubMed ID: 20534387
[TBL] [Abstract][Full Text] [Related]
14. Palliative chemotherapy for recurrent and metastatic esophageal cancer.
Grünberger B; Raderer M; Schmidinger M; Hejna M
Anticancer Res; 2007; 27(4C):2705-14. PubMed ID: 17695436
[TBL] [Abstract][Full Text] [Related]
15. Developing innovative strategies for advanced transitional cell carcinoma of the bladder.
Pollera CF; Nelli F
Expert Rev Anticancer Ther; 2006 Jan; 6(1):83-92. PubMed ID: 16375647
[TBL] [Abstract][Full Text] [Related]
16. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
Pectasides D; Pectasides M; Economopoulos T
Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
[TBL] [Abstract][Full Text] [Related]
17. Bladder preservation: optimizing radiotherapy and integrated treatment strategies.
Mak RH; Zietman AL; Heney NM; Kaufman DS; Shipley WU
BJU Int; 2008 Nov; 102(9 Pt B):1345-53. PubMed ID: 19035903
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for urothelial carcinoma.
Gartrell BA; Sonpavde G
Expert Opin Emerg Drugs; 2013 Dec; 18(4):477-94. PubMed ID: 24195728
[TBL] [Abstract][Full Text] [Related]
19. [The effectiveness of S-1 based sequential chemotherapy as second-line treatment for advanced/recurrent gastric cancer].
Sugimoto N; Narahara H; Sakai D; Yamamoto S; Fumoto S; Yagi T; Imamura F; Iishi H; Tatsuta M
Gan To Kagaku Ryoho; 2009 Mar; 36(3):417-24. PubMed ID: 19295265
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapeutic options for cisplatin-ineligible patients with advanced carcinoma of the urothelium.
Vaughn DJ
Cancer Treat Rev; 2008 Jun; 34(4):328-38. PubMed ID: 18262363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
